C:\Program Files\Stnexp\Queries\10820647 (a).str





chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 19
ring nodes :
22 23 24 25 26 27
chain bonds :
1-2 2-3 3-4 4-5 5-6 6-19 8-9 8-10 11-12 11-13 11-14
ring bonds :
22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
6-19 8-9 8-10 11-12 11-13
exact bonds :
1-2 2-3 3-4 4-5 5-6 11-14
normalized bonds :
22-23 22-27 23-24 24-25 25-26 26-27
isolated ring systems :
containing 22 :

G1:[*1],[*2],[*3]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 19:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
Generic attributes :

6:
Saturation : Unsaturated
7:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

=>
Uploading C:\Program Files\Stnexp\Queries\10820647.str

chain nodes :
1 2 4 5 6 7 8 9 10 11 12 13 14 15 16 21
chain bonds :
1-2 1-4 4-5 5-6 6-7 7-8 8-21 10-11 10-12 13-14 13-15 13-16
exact/norm bonds :
1-2 8-21 10-11 10-12 13-14 13-15
exact bonds :
1-4 4-5 5-6 6-7 7-8 13-16

G1:[*1],[*2],[*3]

Match level :
1:CLASS 2:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 21:CLASS
Generic attributes :
2:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic
8:
Saturation : Unsaturated
9:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 2: Limited
C,C4
N,N2
O,O0
S,S0

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2],[@3]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 20:04:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 97691 TO ITERATE

2.0% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1935274 TO 1972366
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10820647 (a).str





chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 19
ring nodes :
22 23 24 25 26 27
chain bonds :
1-2 2-3 3-4 4-5 5-6 6-19 8-9 8-10 11-12 11-13 11-14
ring bonds :
22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
6-19 8-9 8-10 11-12 11-13
exact bonds :
1-2 2-3 3-4 4-5 5-6 11-14
normalized bonds :
22-23 22-27 23-24 24-25 25-26 26-27
isolated ring systems :
containing 22 :

G1:[*1],[*2],[*3]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 19:CLASS 22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
Generic attributes :

6:
Saturation : Unsaturated
7:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 [@1],[@2],[@3]

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam
SAMPLE SEARCH INITIATED 20:05:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2715 TO ITERATE

73.7% PROCESSED 2000 ITERATIONS 10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 51175 TO 57425
PROJECTED ANSWERS: 50 TO 492

L4 10 SEA SSS SAM L3

```
=> => s l3 sss ful
FULL SEARCH INITIATED 20:06:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    54994 TO ITERATE

100.0% PROCESSED    54994 ITERATIONS                          139 ANSWERS
SEARCH TIME: 00.00.01

L5          139 SEA SSS FUL L3

=> => s l5
L6            6 L5

=> d l6 1-6 bib,ab,hitstr
```

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:927049 CAPLUS
DN 141:379940
TI A preparation of hydroxypropylamine derivatives, useful as modulators of peroxisome proliferator activated receptors (PPARs)
IN Liu, Kevin; Zhao, Cunxiang
PA Kalypsys, Inc., USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English

Appl.

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093879	A1	20041104	WO 2004-US10970	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004231554	A1	20041104	AU 2004-231554	20040407
CA 2520908	AA	20041104	CA 2004-2520908	20040407
US 2005070532	A1	20050331	US 2004-820647	20040407
EP 1613326	A1	20060111	EP 2004-759820	20040407
EP 1613326	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009763	A	20060509	BR 2004-9763	20040407
CN 1791409	A	20060621	CN 2004-80010350	20040407
AT 339205	E	20061015	AT 2004-759820	20040407
JP 2006523698	T2	20061019	JP 2006-509849	20040407
PRAI US 2003-464581P	P	20030417		
WO 2004-US10970	W	20040407		

OS MARPAT 141:379940

AB The invention relates to a preparation of hydroxypropylamine derivs. of formula I [wherein: X is (mono/bi/tri)cyclic aryl ring; Y is (mono/bi)cyclic heteroarom. ring; B is 5-6-membered heteroaryl ring or (CH2)0-1C(O)-O-(H/alkyl/heteroaryl); R1 is alkyl or 5-6-membered heteroaryl; R2 is H, alkyl, CN, NO2, or 5-6-membered heteroaryl, etc.; R3 is H, alkyl, halogen, OH, or amino, etc.], useful as modulators of peroxisome proliferator activated receptors (PPARs). The disclosed compds. are useful for the treatment of metabolic diseases such as obesity, diabetes, polycystic ovary syndrome, or climacteric, etc. For instance, pyrimidine derivative II (R4 = H; hPPAR α, EC50 > 100 μM; hPPAR γ, EC50 < 1μM) was prepared via etherification from Me (3-hydroxyphenyl)acetate and (pyrimidinylamino)propanol derivative III and subsequent hydrolysis of the obtained ester II (R4 = Me).

IT 784174-88-5P 784174-90-9P 784174-98-7P
784174-99-8P 784175-00-4P 784175-02-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxypropylamine derivs., useful as modulators of PPARs)

RN 784174-88-5 CAPLUS

CN Benzeneacetic acid, 3-[3-[butyl(5-ethyl-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 784174-90-9 CAPLUS

CN Benzeneacetic acid, 3-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



Elected species

RN 784174-98-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 1-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 784174-99-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 784175-00-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 3-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 784175-02-6 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-[3-[butyl(5-ethyl-2-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



IT 784174-89-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxypropylamine derivs., useful as modulators of PPARs)
RN 784174-89-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[butyl(5-ethyl-2-pyrimidinyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:565052 CAPLUS
DN 141:123483
TI Preparation of indaneacetic acid derivatives and their use as pharmaceutical agents
IN Cantin, Louis-David; Choi, Soongyu; Clark, Roger B.; Hentemann, Martin F.; Ma, Xin; Rudolph, Joachim; Liang, Sidney X.; Akuche, Christiana; Lavoie, Rico C.; Chen, Libing; Majumdar, Dyuti; Wickens, Philip L.
PA Bayer Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058174	A2	20040715	WO 2003-US40842	20031219
	WO 2004058174	A3	20041202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2510793	AA	20040715	CA 2003-2510793	20031219
	AU 2003299790	A1	20040722	AU 2003-299790	20031219
	EP 1578715	A2	20050928	EP 2003-800063	20031219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006516251	T2	20060629	JP 2004-563903	20031219
	US 2006084680	A1	20060420	US 2005-537630	20050603
PRAI	US 2002-435310P	P	20021220		
	WO 2003-US40842	W	20031219		

OS MARPAT 141:123483
AB The title compds. [I; R1, R2 = H, alkyl, cycloalkyl; L = (CH2)mX, Y(CH2)nX, etc.; X = O, S, SO, SO2, Y = O, S, SO, SO2, (un)substituted NH; m = 1-3; n = 2-4; Ar = (un)substituted Ph, 5-6 membered heteroaryl containing up to there N atoms] which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases, were prepared and formulated. Thus, coupling Et {(1S)-5-[3-(4-bromo-2-methoxyphenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl}acetate (preparation given) with 3-thiopheneboronic acid in the presence of PdCl2(dppf).CH2Cl2, NaHCO3 in DME/H2O followed by treatment of the resulting ester with LiOH afforded (1S)-II.
IT 724468-56-8P 724468-57-9P 724468-66-0P
724468-67-1P 724469-17-4P 724469-18-5P
724469-20-9P 724469-81-2P 724469-82-3P
724470-36-4P 724470-37-5P 724470-38-6P
724470-39-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724468-56-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(5-bromo-2-pyrimidinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-57-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(5-bromo-2-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-66-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-67-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-17-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-18-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-20-9 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(3-methoxyphenoxy)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-81-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-82-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)propylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-36-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(2,5-dichloro-4-pyrimidinyl)amino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-37-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(2,5-dichloro-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-38-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-39-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 724468-58-0P 724468-59-1P 724468-60-4P
724468-61-5P 724468-62-6P 724468-63-7P
724468-64-8P 724468-68-2P 724468-69-3P
724468-70-6P 724468-71-7P 724468-72-8P
724468-73-9P 724468-74-0P 724468-75-1P
724469-19-6P 724469-21-0P 724469-22-1P
724469-23-2P 724469-24-3P 724469-25-4P
724469-26-5P 724469-27-6P 724469-28-7P
724469-29-8P 724469-30-1P 724469-31-2P
724469-32-3P 724469-33-4P 724469-34-5P
724469-35-6P 724469-36-7P 724469-37-8P
724469-38-9P 724469-39-0P 724469-40-3P
724469-41-4P 724469-42-5P 724469-43-6P
724469-44-7P 724469-49-2P 724469-50-5P
724469-51-6P 724469-52-7P 724469-53-8P
724469-54-9P 724469-55-0P 724469-56-1P
724469-57-2P 724469-58-3P 724469-59-4P
724469-60-7P 724469-61-8P 724469-62-9P
724469-63-0P 724469-64-1P 724469-65-2P
724469-66-3P 724469-67-4P 724469-68-5P
724469-69-6P 724469-70-9P 724469-71-0P
724469-72-1P 724469-73-2P 724469-74-3P
724469-75-4P 724469-76-5P 724469-77-6P
724469-78-7P 724469-79-8P 724469-80-1P
724469-83-4P 724469-84-5P 724469-85-6P
724469-86-7P 724469-87-8P 724469-88-9P
724469-90-3P 724469-92-5P 724469-94-7P
724469-96-9P 724469-97-0P 724469-98-1P
724470-00-2P 724470-02-4P 724470-04-6P
724470-05-7P 724470-07-9P 724470-09-1P
724470-11-5P 724470-13-7P 724470-15-9P
724470-17-1P 724470-19-3P 724470-21-7P

724470-23-9P 724470-25-1P 724470-27-3P
724470-29-5P 724470-40-0P 724470-41-1P
724470-42-2P 724470-43-3P 724470-44-4P
724470-45-5P 724470-46-6P 724470-47-7P
724470-48-8P 724470-49-9P 724470-50-2P
724470-51-3P 724470-52-4P 724478-26-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indaneacetic acid derivs. for treating diabetes, obesity, hyperlipidemia, and atherosclerotic diseases)

RN 724468-58-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-ethylphenyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-59-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-60-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-fluorophenyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-61-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-(4-methoxyphenyl)-2-pyrimidinyl]methylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-62-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-[4-(1,1-dimethylethyl)phenyl]-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-63-7 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-(3-thienyl)-2-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-64-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(5-benzo[b]thien-2-yl-2-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-68-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-69-3 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-70-6 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[propyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-71-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-2-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-72-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(4-ethylphenyl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-73-9 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[4-(4-methoxyphenyl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-74-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(4-chlorophenyl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724468-75-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[4-(1,3-benzodioxol-5-yl)-5-(trifluoromethyl)-2-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-19-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-21-0 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-22-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-23-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-24-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-25-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-26-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-27-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3,4-dimethoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-28-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-29-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-30-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-31-2 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-32-3 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-33-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-34-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3-fluoro-4-methylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-35-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3-ethoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-36-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-37-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-38-9 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-39-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-40-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-41-4 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl(5-methyl-2-phenyl-4-pyrimidinyl)amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-42-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-(3-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-43-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(3-chlorophenyl)-5-methyl-4-

pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-44-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-49-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-50-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-51-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-52-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-53-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-chlorophenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-54-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(5-fluoro-2-phenyl-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-55-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-56-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-57-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-58-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-fluoro-2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-59-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-60-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-61-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-ethyl-2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-62-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-ethyl-2-(4-ethylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-63-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-ethyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-64-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-65-2 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[6-methyl-2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-66-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethoxyphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-67-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-cyclohexylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-68-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-butylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-69-6 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[6-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-70-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-[4-(1,1-dimethylethyl)phenyl]-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-71-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-acetylphenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-72-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-73-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-74-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(2-fluorophenyl)-6-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-75-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(2-chloro-4-pyrimidinyl)methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-76-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[methyl[5-methyl-2-(3-thienyl)-4-

pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-77-6 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenoxy)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-78-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenoxy)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-79-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(2-benzofuranyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-80-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(2-benzofuranyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-83-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-84-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[(6-phenyl-4-pyrimidinyl)amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-85-6 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-86-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-87-8 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-88-9 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-90-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-92-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-thienyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-94-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-96-9 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-methylphenyl)-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-97-0 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(3-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724469-98-1 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-00-2 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-02-4 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-04-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-05-7 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-thienyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-07-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-09-1 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[5-methyl-2-(3-methylphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-11-5 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methylphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-13-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-15-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-4-pyrimidinyl]propylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-17-1 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(4-methoxyphenyl)-4-pyrimidinyl]propylamino]propoxy]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-19-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[(cyclopropylmethyl)[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-21-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[ethyl[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-23-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[ethyl[5-methyl-2-(4-methylphenyl)-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-25-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]ethylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-27-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[acetyl[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-29-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[acetyl[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]amino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-40-0 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-41-1 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-42-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-acetylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-43-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-44-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2,5-bis(4-fluorophenyl)-4-

pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-45-5 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-ethylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-46-6 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-47-7 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-(4-acetylphenyl)-2-chloro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-48-8 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-49-9 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[5-(1,3-benzodioxol-5-yl)-2-chloro-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-50-2 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-51-3 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(4-methylphenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724470-52-4 CAPLUS
CN 1H-Indene-1-acetic acid, 5-[3-[[2-chloro-5-(3,4-difluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-2,3-dihydro-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724478-26-6 CAPLUS
CN 1H-Indene-1-acetic acid, 2,3-dihydro-5-[3-[[2-(3-methoxyphenoxy)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, ethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:78227 CAPLUS
DN 134:131078
TI Preparation of bicyclic antagonists selective for the αvβ3 integrin
IN Zask, Arie; Hauze, Diane Barbara; Kees, Kenneth Lewis; Coghlan, Richard Dale; Yardley, John
PA American Home Products Corporation, USA
SO PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007036	A1	20010201	WO 2000-US19885	20000720
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2378860	AA	20010201	CA 2000-2378860	20000720
	BR 2000012683	A	20020416	BR 2000-12683	20000720
	EP 1198231	A1	20020424	EP 2000-950508	20000720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 6429214	B1	20020806	US 2000-620381	20000720
	JP 2003505416	T2	20030212	JP 2001-511922	20000720
	US 2003109523	A1	20030612	US 2002-163844	20020606
PRAI	US 1999-172238P	P	19990721		
	US 1999-358035	A	19990721		
	US 2000-620381	A3	20000720		
	WO 2000-US19885	W	20000720		

OS MARPAT 134:131078
AB This invention provides novel bicyclic compds. I and II (tetrahydro- and dihydroquinolines, tetrahydronaphthalenes and tetrahydro-6H-benzocycloheptenes) or pharmaceutically acceptable salts thereof that exhibit activity as inhibitors of bone resorption with minimal inhibition of platelet aggregation mediated by αIIbβ3 integrin. An example is [6-(3-guanidinopropoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]acetic acid-trifluoroacetate. Results are reported for some of the claimed compds. for vitronectin receptor (αvβ3) binding, effect on integrin (αvβ3)-mediated attachment of cells to osteopontin, osteoclast bone pitting, effects on PTH-induced hypercalcemia of thyro-parathyroidectomized male rats, effects on serum calcium in TPTX male rats treated with rPTH(1-34), and effect on ADP-induced platelet aggregation. In I and II, the dotted line represents the presence of an optional double bond. N = 2-5. V = 0, 1. A-B = diradical -CH2(CH2)m- or -NR5C(O)-. M = 1, 2. Y = -O-, -CH2CH2-, -CH:CH-, -C.tplbond.C-, -NR1aC(O)-. R1 = H or straight chain alkyl of 1-6 C atoms; phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with one or more substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7

C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms; heterocycloalkyl, wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the heterocyclo moiety is selected from a 5- or 6-membered heterocyclic ring which contains 1-3 heteroatoms which may be the same or different, selected from N, O and S optionally substituted with ≥1 substituents which may be the same or different, and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, cyano and nitro. R1a = H or straight chain alkyl of 1-6 C atoms; phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. R2 = H, -NHR1, or -OR1, aryl of 6-12 C atoms optionally substituted with ≥1 substituents selected from straight chain alkyl of 1-6 C atoms, alkoxy of 1-6 C atoms, -S-alkyl of 1-6 C atoms, cyano, nitro, halogen and phenyl; the heterocyclic moiety is selected from a 5- or 6-membered heterocyclic ring which contains 1-3 heteroatoms which may be the same or different, selected from N, O and S optionally substituted with ≥1 substituents which may be the same or different, and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, cyano and nitro; phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms; heterocycloalkyl, wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the heterocyclic moiety is selected from a 5- or 6-membered heterocyclic ring which contains 1-3 heteroatoms which may be the same or different, selected from N, O and S optionally substituted with ≥1 substituents which may be the same or different, and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, cyano and nitro. G is a N-containing moiety selected from H2NC(:NH)-, R4C(O)NHC(:NC(O)R4)-, R1NHC(O)-, 2-pyrimidinyl, 1,4,5,6-tetrahydropyrimidin-2-yl, 6-amino-2-pyridinyl, 2-pyridinyl, 2-imidazolin-2-yl, 3-amino-1,2,4-triazol-5-yl, III and IV. U = 0, 1. R4 = straight chain alkyl of 1-6 C atoms, alkoxy or phenylalkyloxy wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. R5 = H, straight chain alkyl of 1-6 C atoms, or phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms and dialkylamino of 1-6 C atoms. R5a = H, straight chain alkyl of 1-6 C atoms, or phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. R5b = H, straight chain alkyl of 1-6 C atoms, or phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same

or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. The optional double bond is a single bond when A-B is the diradical -CH2(CH2)m-. In II, D = OR3, NHSO2C6H3R5aR5b; R3 = H, straight chain alkyl of 1-6 C atoms optionally substituted with a group selected from amino, hydroxyl and carboxyl or branched chain alkyl of 3-7 C atoms optionally substituted with a group selected from amino, hydroxyl and carboxyl; certain combinations of values of variables are excluded as described in the claims. Pharmaceutical compns. containing the above compds. are claimed to be useful against mammalian bone resorption diseases selected from osteoporosis, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization-induced osteopenia and the result of glucocorticoid treatment. Although the methods of preparation of the compds. are not claimed, >200 example prepns. of products and intermediates are given.

IT 321886-47-9P, {6-[3-(Pyrimidin-2-ylamino)propoxy]-1,2,3,4-tetrahydronaphthalen-2-yl}acetic acid methyl ester
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic antagonists selective for αvβ3 integrin)

RN 321886-47-9 CAPLUS

CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-6-[3-(2-pyrimidinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 321886-48-0P, [6-[3-(Pyrimidin-2-ylamino)propoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]acetic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic antagonists selective for αvβ3 integrin)

RN 321886-48-0 CAPLUS

CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-6-[3-(2-pyrimidinylamino)propoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:222921 CAPLUS
DN 130:267229
TI Preparation of dibenzo[a,d]cycloheptene-10-acetic acid derivatives as vitronectin receptor antagonists
IN Bondinell, William E.; Miller, William H.; Heerding, Dirk; Samanen, James Martin
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915508	A1	19990401	WO 1998-US19466	19980918
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9808562	A	19990319	ZA 1998-8562	19980918
	CA 2303487	AA	19990401	CA 1998-2303487	19980918
	AU 9893972	A1	19990412	AU 1998-93972	19980918
	AU 738433	B2	20010920		
	EP 1025090	A1	20000809	EP 1998-947116	19980918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	TR 200000721	T2	20001121	TR 2000-200000721	19980918
	HU 200003641	A2	20010328	HU 2000-3641	19980918
	JP 2001517658	T2	20011009	JP 2000-512816	19980918
	BR 9812340	A	20011218	BR 1998-12340	19980918
	NZ 503389	A	20020328	NZ 1998-503389	19980918
	TW 513303	B	20021211	TW 1998-87115535	19980923
	NO 2000001407	A	20000317	NO 2000-1407	20000317
	BG 104314	A	20010131	BG 2000-104314	20000407
	US 2002091264	A1	20020711	US 2001-22987	20011217
	US 6576643	B2	20030610		
PRAI	US 1997-59342P	P	19970919		
	US 1997-63438P	P	19971029		
	WO 1998-US19466	W	19980918		
	US 2000-508574	B1	20000313		

OS MARPAT 130:267229
AB The title compds. I [A = CH2, O; R1 = H, halo, C1-6alkyl; R2 = H, C1-6alkyl, CH2NR''R''; X = O, CH2; Y = Q, Q1, etc.], vitronectin receptor antagonists, were prepared E.g., (S)-10,11-dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid was prepared
IT 206124-62-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dibenzo[a,d]cycloheptene-10-acetic acid derivs. as vitronectin receptor antagonists)
RN 206124-62-1 CAPLUS
CN 5H-Dibenzo[a,d]cycloheptene-10-acetic acid, 10,11-dihydro-3-[3-(2-pyrimidinylamino)propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:239115 CAPLUS
DN 128:294793
TI Preparation of benzodiazepines and dibenzo[a,d]cycloheptanes for stimulating bone formation
IN Drake, Fred H.
PA Smithkline Beecham Corporation, USA; Drake, Fred H.
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9815278	A1	19980416	WO 1997-US18178	19971007
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 946180	A1	19991006	EP 1997-945563	19971007
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2001501951	T2	20010213	JP 1998-517727	19971007
	US 2002032187	A1	20020314	US 2001-956659	20010920
PRAI	US 1996-27764P	P	19961007		
	WO 1997-US18178	W	19971007		
	US 1999-284055	B1	19990407		
	US 2000-639347	A1	20000816		

OS MARPAT 128:294793
AB The title compds. [I or II; X-X1 = NR1CH, N:C, CR1:C, etc.; R1 = H, C1-6 alkyl, Ar-C1-6 alkyl; R2 = (CH2)nCO2R'; R3 = H, C1-6 alkyl, Ar-C0-6 alkyl, etc.; R4 = W-(Q')p(CR'2)qU(CR'2)s; R' = H, C1-6 alkyl, C3-7 cycloalkyl, etc.; Q' = NR5, S, CR5; U = NR6C(O), C(O)NR6, CH2CO, etc.; R5, R6 = H, C1-6 alkyl, etc.; W = (un)substituted pyridyl, piperidinyl, imidazolyl, etc.; n = 1-2; p = 0-1; q = 0-3; s = 0-3], integrin binding compds. which cause the release of osteocalcin from osteoblasts, and are therefore useful for treating osteoporosis, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, or bone loss due to immobilization or sex hormone deficiency, were prepared and formulated. Thus, treatment of Me (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate with SOCl2 followed by reaction of the resulting intermediate with 2-(aminomethyl)benzimidazole.2HCl in the presence of pyridine and Et3N in CH2Cl2, and hydrolysis of the acetate with 1.0 LiOH in THF/H2O afforded the title compound I [X = NH; X1 = CH; R2 = CH2COOH; R3 = Me; R4 = {[(2-benzimdazolyl)methyl]amino}carbonyl]. Prepared compds. I or II showed EC50 of < 1 μM in the ROS 17/2.8 osteocalcin assay.
IT 206124-62-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzodiazepines and dibenzo[a,d]cycloheptanes for stimulating bone formation)
RN 206124-62-1 CAPLUS
CN 5H-Dibenzo[a,d]cycloheptene-10-acetic acid, 10,11-dihydro-3-[3-(2-pyrimidinylamino)propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:186224 CAPLUS
DN 104:186224
TI Inhibitors of dihydropteroate synthase: substituent effects in the side-chain aromatic ring of 6-[[3-(aryloxy)propyl]amino]-5-nitrosoisocytosines and synthesis and inhibitory potency of bridged 5-nitrosoisocytosine-p-aminobenzoic acid analogs
AU Lever, O. William, Jr.; Bell, Lawrence N.; Hyman, Clifton; McGuire, H. Michael; Ferone, Robert
CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (1986), 29(5), 665-70
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 104:186224
AB Cytosine derivs. I [X = O, NH, n = 3; X = NH, n = 4; R = C6H4R1-4, C6H3Cl2-3,5, C6H3(OMe)2-3,5, C6H2(OMe)3-3,4,5, C6H4OCH2Ph-2; R1 = H, OH, OMe, OBu, OCH2Ph, SO2Me, CF3, NO2, Cl, NHSO2C6H4Me-4, CO2Et, CO2H] were prepared by treating the methylthiopyrimidine with H2N(CH2)nXR, prepared from phthalimidoalkyl bromides and RXH. The dihydropteroate synthase (II)-inhibiting activity of I was affected by the nature of R; I (X = O) were more active than I (X = NH). Structure-activity considerations and enzyme inhibition kinetics did not support the PABA binding site as the II region that interacts with I. I had no significant bactericidal activity.
IT 100840-88-8P 100840-89-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, hydrolysis, and dihydropteroate synthase inhibition by)
RN 100840-88-8 CAPLUS
CN Benzoic acid, 4-[3-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]propoxy]-, ethyl ester (9CI) (CA INDEX NAME)



2 Diff

RN 100840-89-9 CAPLUS
CN Benzoic acid, 4-[3-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]propoxy]- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 20:03:29 ON 12 DEC 2006)

     FILE 'REGISTRY' ENTERED AT 20:03:37 ON 12 DEC 2006
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4          10 S L3 SSS SAM
L5         139 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 20:06:30 ON 12 DEC 2006
L6           6 S L5

     FILE 'CAOLD' ENTERED AT 20:06:58 ON 12 DEC 2006

=> s l5
L7           0 L5

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44     200.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -4.50

STN INTERNATIONAL LOGOFF AT 20:07:11 ON 12 DEC 2006
```